TNX-1500
Organ Transplant Rejection / Autoimmune Disorders
Phase 1Clinical Phase Complete
Key Facts
Indication
Organ Transplant Rejection / Autoimmune Disorders
Phase
Phase 1
Status
Clinical Phase Complete
Company
About Tonix Pharmaceuticals
Tonix Pharmaceuticals is a clinical-stage biotech focused on addressing difficult-to-treat conditions across CNS, immunology, infectious diseases, and rare diseases. Its strategy leverages multiple technology platforms, including a sublingual delivery system, a live virus vaccine platform, and monoclonal antibody development, to advance a broad pipeline. Key near-term catalysts include Phase 2 data for TNX-102 SL in Acute Stress Disorder and the progression of its Phase 2-ready programs in organ transplant rejection and Prader-Willi Syndrome.
View full company profile